Novavax RSV Vaccine Fails to Hit Primary Endpoint in Phase III Trial - BioSpace

1. Novavax RSV Vaccine Fails to Hit Primary Endpoint in Phase III Trial  BioSpace
2. Can Novavax Convince the FDA Its Vaccine Deserves a Chance?  Motley Fool
3. Novavax (NVAX) Stock: Working To Recover  CNA Finance
4. Novavax shares crater 69% premarket after trial of ResVax misses its main goal  MarketWatch
5. Novavax (NASDAQ:NVAX) Re-Enters Penny Stock Territory After Respiratory Disease Vaccine Flunks Late-Stage Trial  Benzinga
6. View full coverage on Google News

(CLICK HERE TO READ AND SEE MORE)